Pipeline Programs↗
Distinct drugs in development (Preclinical–Phase 3)
Indications↗
Distinct diseases across all programs
Clinical Trials↗
All sponsored trials (all statuses)
Pipeline
By Phase
32 drugs in development
By Therapeutic Area
top 6
R&D Momentum
100/100
Pipeline Velocity
92/100
Trial Completion Rate
66/100
Pipeline Concentration
22/100
Pipeline Freshness
76/100
Strategic Signals
Activity
Last 14 days
Molecular Residual Disease (MRD) Guided Adjuvant ThErapy in Renal Cell Carcinoma (RCC)
Early Withdrawal Exposure and Negative Affect Withdrawal (NAW) Regulation Training for Smoking Cessation
A Pilot Study to Evaluate the Safety and Efficacy of Baricitinib in the Treatment of Frontal Fibrosing Alopecia (FFA)
Providing an Optimized and emPowered Pregnancy for You (PᵌOPPY) Aim 3: Randomized Controlled Trial
Trauma Communications Center Coordinated Severity-Based Stroke Triage
Telemedicine for Unhealthy Alcohol Use in Persons Living With HIV Using Common Elements Treatment Approach
Brain Training for Chronic, Post-viral, Brain Fog: Study A
Details
Company Overview
—
Mkt Cap
—
Revenue
—
Cash
Pipeline
Regulatory
Omnipaque — OMNIPAQUE 140, OMNIPAQUE 300, OMNIPAQUE 180, OMNIPAQUE 9, OMNIPAQUE 210, OMNIPAQUE 350, OMNIPAQUE 240, OMNIPAQUE 12, OMNIPAQUE 70
Application NDA018956
Omnipaque — OMNIPAQUE 140, OMNIPAQUE 300, OMNIPAQUE 180, OMNIPAQUE 9, OMNIPAQUE 210, OMNIPAQUE 350, OMNIPAQUE 240, OMNIPAQUE 12, OMNIPAQUE 70
Application NDA018956
Omnipaque — OMNIPAQUE 140, OMNIPAQUE 300, OMNIPAQUE 180, OMNIPAQUE 9, OMNIPAQUE 210, OMNIPAQUE 350, OMNIPAQUE 240, OMNIPAQUE 12, OMNIPAQUE 70
Application NDA018956
Omnipaque — OMNIPAQUE 350, OMNIPAQUE 240, OMNIPAQUE 300
Application NDA020608
Omnipaque — OMNIPAQUE 140, OMNIPAQUE 300, OMNIPAQUE 180, OMNIPAQUE 9, OMNIPAQUE 210, OMNIPAQUE 350, OMNIPAQUE 240, OMNIPAQUE 12, OMNIPAQUE 70
Application NDA018956
Omnipaque — OMNIPAQUE 350, OMNIPAQUE 240, OMNIPAQUE 300
Application NDA020608
Omnipaque — OMNIPAQUE 350, OMNIPAQUE 240, OMNIPAQUE 300
Application NDA020608
Omnipaque — OMNIPAQUE 350, OMNIPAQUE 240, OMNIPAQUE 300
Application NDA020608
Omnipaque — OMNIPAQUE 140, OMNIPAQUE 300, OMNIPAQUE 180, OMNIPAQUE 9, OMNIPAQUE 210, OMNIPAQUE 350, OMNIPAQUE 240, OMNIPAQUE 12, OMNIPAQUE 70
Application NDA018956
Omnipaque — OMNIPAQUE 350, OMNIPAQUE 240, OMNIPAQUE 300
Application NDA020608
Omnipaque — OMNIPAQUE 140, OMNIPAQUE 300, OMNIPAQUE 180, OMNIPAQUE 9, OMNIPAQUE 210, OMNIPAQUE 350, OMNIPAQUE 240, OMNIPAQUE 12, OMNIPAQUE 70
Application NDA018956
Omnipaque — OMNIPAQUE 140, OMNIPAQUE 300, OMNIPAQUE 180, OMNIPAQUE 9, OMNIPAQUE 210, OMNIPAQUE 350, OMNIPAQUE 240, OMNIPAQUE 12, OMNIPAQUE 70
Application NDA018956
Omnipaque — OMNIPAQUE 140, OMNIPAQUE 300, OMNIPAQUE 180, OMNIPAQUE 9, OMNIPAQUE 210, OMNIPAQUE 350, OMNIPAQUE 240, OMNIPAQUE 12, OMNIPAQUE 70
Application NDA018956
Omnipaque — OMNIPAQUE 140, OMNIPAQUE 300, OMNIPAQUE 180, OMNIPAQUE 9, OMNIPAQUE 210, OMNIPAQUE 350, OMNIPAQUE 240, OMNIPAQUE 12, OMNIPAQUE 70
Application NDA018956
Omnipaque — OMNIPAQUE 350, OMNIPAQUE 240, OMNIPAQUE 300
Application NDA020608
Omnipaque — OMNIPAQUE 140, OMNIPAQUE 300, OMNIPAQUE 180, OMNIPAQUE 9, OMNIPAQUE 210, OMNIPAQUE 350, OMNIPAQUE 240, OMNIPAQUE 12, OMNIPAQUE 70
Application NDA018956
Omnipaque — OMNIPAQUE 140, OMNIPAQUE 300, OMNIPAQUE 180, OMNIPAQUE 9, OMNIPAQUE 210, OMNIPAQUE 350, OMNIPAQUE 240, OMNIPAQUE 12, OMNIPAQUE 70
Application NDA018956
Omnipaque — OMNIPAQUE 350, OMNIPAQUE 240, OMNIPAQUE 300
Application NDA020608
Omnipaque — OMNIPAQUE 350, OMNIPAQUE 240, OMNIPAQUE 300
Application NDA020608
Omnipaque — OMNIPAQUE 140, OMNIPAQUE 300, OMNIPAQUE 180, OMNIPAQUE 9, OMNIPAQUE 210, OMNIPAQUE 350, OMNIPAQUE 240, OMNIPAQUE 12, OMNIPAQUE 70
Application NDA018956
Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)